Susquehanna International Group, LLP Morphic Holding, Inc. Call Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 07, 2024	SELL	$26.64 - $40.31 $42,624 - $64,496	-1,600 Reduced 15.38%	8,800 $309,000
Q4 2023 Feb 14, 2024	SELL	$19.95 - $31.0 $2.19 Million - $3.4 Million	-109,800 Reduced 91.35%	10,400 $300,000
Q3 2023 Nov 14, 2023	BUY	$21.33 - $59.42 $1.41 Million - $3.93 Million	66,200 Added 122.59%	120,200 $2.75 Million
Q2 2023 Aug 11, 2023	SELL	$34.33 - $62.11 $1.02 Million - $1.84 Million	-29,700 Reduced 35.48%	54,000 $3.1 Million
Q1 2023 May 16, 2023	BUY	$26.01 - $48.69 $2.18 Million - $4.08 Million	83,700 New	83,700 $3.15 Million
Q2 2022 Aug 15, 2022	SELL	$19.74 - $43.01 $209,243 - $455,906	-10,600 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$36.25 - $52.02 $384,250 - $551,412	10,600 New	10,600 $426,000

4.7M

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.